Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shenzhen Salubris Pharmaceuticals Co Ltd operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for Shenzhenlubris Pharmaceuticals Co's Operating Margin % or its related term are showing as below:
SZSE:002294'
s Operating Margin % Range Over the Past 10 Years
Min: 13.45 Med: 19.17 Max: 41.85
Current: 17
SZSE:002294's Operating Margin % is ranked better than 75.21% of 960
companies
in the Drug Manufacturers industry
Industry Median: 7.42
vs SZSE:002294: 17.00
Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Shenzhenlubris Pharmaceuticals Co Operating Margin % Related Terms
Shenzhenlubris Pharmaceuticals Co Operating Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhenlubris Pharmaceuticals Co Operating Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhenlubris Pharmaceuticals Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhenlubris Pharmaceuticals Co Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shenzhenlubris Pharmaceuticals Co's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Shenzhenlubris Pharmaceuticals Co's Operating Margin % falls into.
Shenzhenlubris Pharmaceuticals Co Operating Margin % Calculation
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhenlubris Pharmaceuticals Co (SZSE:002294) has a Operating Margin % of 20.21% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Shenzhenlubris Pharmaceuticals Co and its competitors. This is near median its historical median of 19.17. Over the past decade, Shenzhenlubris Pharmaceuticals Co's Operating Margin % has ranged from 13.45 to 41.85. According to the industry distribution chart, Shenzhenlubris Pharmaceuticals Co ranks #238 out of 960 companies in the Drug Manufacturers industry, placing it in the top 24.8%.
Is Shenzhenlubris Pharmaceuticals Co's Operating Margin % too high?
Shenzhenlubris Pharmaceuticals Co's current Operating Margin % of 20.21% is near median its 10-year median of 19.17. Over the past 10 years, this metric has ranged from a low of 13.45 to a high of 41.85. The Drug Manufacturers industry median Operating Margin % is 7.42. Shenzhenlubris Pharmaceuticals Co's value of 20.21% is 172.4% above this industry median. Based on the distribution chart, Shenzhenlubris Pharmaceuticals Co ranks #238 out of 960 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Shenzhenlubris Pharmaceuticals Co has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shenzhenlubris Pharmaceuticals Co's Operating Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shenzhenlubris Pharmaceuticals Co ranks #238 out of 960 companies for Operating Margin %. This places Shenzhenlubris Pharmaceuticals Co in the top 25% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 7.42. Shenzhenlubris Pharmaceuticals Co's value of 20.21% is 172.4% above this benchmark. Historically, Shenzhenlubris Pharmaceuticals Co's own Operating Margin % has ranged from 13.45 to 41.85 over the past decade. While the company's 10-year median is 19.17 vs. the industry median of 7.42, Shenzhenlubris Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.42, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shenzhenlubris Pharmaceuticals Co's current Operating Margin % of 20.21% is 172.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Shenzhenlubris Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhenlubris Pharmaceuticals Co's current Operating Margin % is 20.21%, which is near median its own 10-year median of 19.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhenlubris Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhenlubris Pharmaceuticals Co (SZSE:002294) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥44.01, compared to a current price of ¥33.85 — trading 23.1% below its estimated fair value. The current Operating Margin % is 20.21%, which is near median its 10-year median of 19.17 and 172.4% above the Drug Manufacturers industry median of 7.42. Shenzhenlubris Pharmaceuticals Co's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Shenzhenlubris Pharmaceuticals Co (SZSE:002294), the current Operating Margin % is 20.21% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhenlubris Pharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥33.85 is trading 23.1% below its estimated GF Value™ of ¥44.01.
GuruFocus considers Shenzhenlubris Pharmaceuticals Co to be Modestly Undervalued.
Key valuation signals for SZSE:002294:
Operating Margin %: 20.21% (near median its 10-year median of 19.17)
GF Value™: ¥44.01 vs. price of ¥33.85 (23.1% below fair value)
Industry Position: 172.4% above the Drug Manufacturers median (#238 of 960)
No single metric tells the full story. See the SZSE:002294 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalosporins, and bone resorption inhibitors. Its products mainly focus on the areas of cardio-cerebral vascular disease, diabetes, complications, anti-tumor, and orthopedics. Its business lines include high-end chemical drugs, biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other countries and regions.
82GF Score
Get the complete analysis for SZSE:002294
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:002294 has been successfully added to your 
